Boston Scientific Corp (BSX) stock forecast · P/E 20, rev $20.07B
Boston Scientific Corp (BSX) is a medical devices company listed on US.
This BSX forecast page states what the cached financials imply — not a price target and not a guarantee. Boston Scientific Corp outlooks on Lician start from reported revenue and the latest filing, then you decide.
Latest reported BSX revenue for 2025-12-31 was $20.07B. Net income was $2.89B. BSX currently screens at market cap $71.81B and trailing P/E 20.2.
Period-over-period revenue change is not in cache for BSX, so this page does not invent a growth rate.
BSX currently screens at market cap $71.81B and trailing P/E 20.2. Stretching today's multiple into 2026 without a filing reason is how thin forecast pages get ignored.
When the next BSX 10-Q or 8-K lands, this outlook should move. Until then the SEC page is the source.
Not a prediction market. For the live quote and the full model, use the BSX stock page.
Not investment advice.